Preview Mode Links will not work in preview mode

This Week in Cardiology

Sep 24, 2021

Dual antiplatelet therapy after PCI, statin side effects, nightshift work and AF, and a cautionary note regarding therapeutic enthusiasm in HF care are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit:


- Alaska Sets Record for Daily COVID Cases


- MASTER DAPT: 1 Month DAPT Enough After High-Bleeding-Risk PCI

- Antiplatelets and Anticoagulation Post-PCI: More on MASTER DAPT

- Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

- Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial

III - Statins and Side Effects

- Most Muscle Pain on Statins Not a Drug Effect: SAMSON in Print

- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

IV - Nightshift Work and AF

- Regular Nightshift Work Linked to Atrial Fibrillation, CHD

- Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease

V - Enthusiasm for HF Therapy

- Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD

Questions or feedback, please contact